Abstract
Introduction
The inflammatory bowel disease market is set to grow from $2.9 billion in 2008
to $4.5 billion in 2018 across the seven major markets. While Datamonitor' s
updated forecast will parallel its previous forecast up to 2012, several new
product launches, regional expansion and upgraded brand forecast will help to
sustain growth in the second half of the forecast period.
Key reasons to purchase this research
- Understand how new brands Lialda and Apriso will fare against established
market players, such as Asacol and Pentasa
- Assess the impact of the launch of Cimzia' s recent pre-filled syringe and
gauge future dynamics within the anti-TNF class
- Quantify the current and future size of the inflammatory bowel disease
market
Table of Contents
OVERVIEW
- This product contains forecasts for inflammatory bowel disease across the
seven major markets from 2008 to 2018. It has been designed for delivery in an
excel data pack format.
- The associated report and Excel deliverable can be found under Latest
research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
